ReviewDrug design, development and therapy2025
A Bibliometric and Visual Analysis of Oliceridine Research (2013-2024).
Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Effect of Oliceridine Pretreatment on Etomidate-Induced Myoclonus: A Proof-of-Concept Randomized Trial.Drug design, development and therapy · 2026Trial
- ECDrug design, development and therapy · 2026Trial
- A Comparison of Oliceridine versus Sufentanil for Patient-Controlled Analgesia After Total Knee Arthroplasty in Elderly Patients: A Double-Blinded Randomized Controlled Study.Drug design, development and therapy · 2026Trial
- Oliceridine effectively attenuates fentanyl-induced cough during general anesthesia induction.Frontiers in medicine · 2026Trial
- Effect of Oliceridine on Sufentanil-Induced Cough During General Anesthesia: A Prospective Randomized Controlled Clinical Study.Drug design, development and therapy · 2025Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To explore and analyze the current research progress, hotspots, and future trends in oliceridine research using bibliometric methods. Patients and Methods: We searched the Web of Science (WOS) database utilizing the keywords TS = ("oliceridine*" OR "TRV 130*" OR "TRV-130*" OR "olinvyk*" OR "TRV130*" OR "C22H31CIN2O2S*") for relevant research literature on oliceridine from its inception to June 16, 2024. Bibliometric methods were applied, and analysis software such as VOSviewer and CiteSpace were used to visualize the publication timeline, authors, countries and regions, keywords, sources of literature, research hotspots, and co-cited documents related to oliceridine. Co-occurrence and aggregation analyses were conducted, and maps relevant to institutional cooperation were generated. Results: A total of 151 relevant articles were retrieved and included in the final analysis. Most articles were published between 2020 and 2021. The United States has the highest number of publications and citations in this field. Molecular structure development is a pivotal point in this field. Research hotspots were diverse, including acute pain, opioid receptors, β-arrestin, postoperative pain, therapeutic window, respiratory depression, clinical trials, and chronic pain. Conclusion: Oliceridine, a newly developed analgesic, has garnered global interest. The USA is a leading contributor to this field. Recent research has shifted from basic studies to clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.